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The catalytic subunit p110a of the phosphoinositide 3-kinase (PI3K) and the serine– threonine protein kinase Akt have been extensively
studied as retroviral oncoproteins. The experimental tools developed with the retroviral vectors are now being applied to PI3K mutations in
human cancer. The most frequently occurring mutants of p110a are oncogenic in vitro and in vivo, show gain of enzymatic function,
activate Akt, and their oncogenic activity is sensitive to rapamycin. The related isoforms p110h, g and y induce oncogenic transformation
as wild-type proteins. Mutated p110a proteins are ideal drug targets. Identification of small molecule inhibitors that specifically target these
mutant proteins is a realistic and urgent goal.
D 2005 Elsevier Inc. All rights reserved.
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In the late eighties and early nineties, our lab isolated several
oncogenic retroviruses from spontaneous tumors in adult layer
chickens (Cavalieri et al., 1985; Chang et al., 1997; Maki et al.,
1987; Tsuchie et al., 1989). One of these new oncoviruses is
ASV16, which causes rapidly growing hemangiosarcomas in
young chickens and induces oncogenic transformation in
cultures of chicken embryo fibroblasts (Chang et al., 1997).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.027
i This paper is dedicated to the memory of Professor Kazuyoshi Yonezawa of
Kobe, Japan. Professor Yonezawa’s ground-breaking discoveries have deep-
ened our understanding of PI3K signaling.
* Corresponding author.
E-mail address: pkvogt@scripps.edu (P.K. Vogt).Cloning and sequencing of the ASV16 genome revealed a
defective retrovirus that codes for a single protein consisting of
viral Gag sequences fused to a cell-derived insert. These cellular
sequences contained most of the coding region of the catalytic
subunit p110 of phosphoinositide 3-kinase (PI3K). The new
oncoprotein was termed P3K (Fig. 1). Vertebrate genomes code
for several different PI3K proteins that are grouped into three
classes, I–III (Cantley, 2002; Fruman et al., 1998; Vanhaeseb-
roeck and Waterfield, 1999). P3K is derived from the p110a
isoform of class I. In this review, we will consider only class I
PI3Ks, comprising the a, h, g and y isoforms, each of which is
paired to one of multiple regulatory subunits that are isoform-
specific (Table 1).
When ASV16 was cloned in 1997, the identification of a new
retroviral oncoprotein was not considered ‘‘hot news’’, but P3K6) 131 – 138
www.e
Fig. 1. The genome of ASV16. ASV16 is a replication-defective avian sarcoma
virus that lacks all of the pol gene and parts of the gag and env genes. It codes
for a single protein in which sequences derived from the catalytic subunit of
PI3K, p110a, are fused to partial viral Gag sequences. LTR = long terminal
repeat.
Fig. 2. Domain structure of p110a and position of the three most prominent
mutational hot spots. p85 = domain interacting with the regulatory subunit p85,
Ras = Ras-binding domain, C2 = calcium-dependent phospholipid-binding
domain. The principal mutational hot spots are located in the helical and kinase
domains. E542K, E545K and H1047R are typical cancer-specific mutations in
the p110a sequence.
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more than passing attention. A comparison between viral and
cellular P3K sequences revealed several point mutations and a
short N-terminal deletion in viral P3K (Chang et al., 1997). In
addition, the viral P3K was fused at the N-terminus to partial
viral Gag sequences. Since the cellular P3K homolog, p110a, is
not oncogenic by itself, the genetic changes carried by its viral
counterpart must be responsible for the potent oncogenic effect
of viral P3K (Aoki et al., 2000). Experience with other
oncoproteins fused to Gag has shown that the Gag protein can
usually be deleted without loss of oncogenicity (Bos et al., 1990;
Patschinsky et al., 1986; Shaw et al., 1985). In these cases, Gag
may primarily enhance the translation efficiency of the fusion
protein. Therefore, the expectation for the Gag-p110a fusion
was that the point mutations in the p110a sequence rather than
its fusion to Gag constituted the relevant pathogenic change.
This supposition, however, was mistaken. The critical observa-
tions came from studies on cellular p110a. When the wild-type
sequence of that protein was cloned into the RCAS avian
replication-competent retroviral expression vector and intro-
duced into chicken embryo fibroblasts, it did not induce
generalized oncogenic transformation, but only the appearance
of a few, isolated foci of transformed cells (Aoki et al., 2000;
Hughes et al., 1987). These rare foci, emerging after 2 to 3 weeks
of incubation, suggested the presence of a mutation in the
cellular gene that could have activated the latent oncogenic
potential of that gene. The analysis of p110a in these foci
showed that in every case the cellular sequences had become
fused to partial Gag sequences of the RCAS vector (Aoki et al.,
2000). Each focus of transformed cells, containing the progeny
of a single RCAS viral particle, represents an independent fusion
event. The length of the partial Gag sequence differs from focus
to focus. The apparent oncogenicity of the wild-type, cellular
p110a derives from a peculiarity of the RCAS vector system
which generates these random fusions between Gag and the
cellular insert in the course of RCAS viral replication.Table 1
Isoforms of class I phosphoinositide 3-kinases
Class Subunits Tissue distribution
Regulatory Catalytic




p110y Mainly in leukocytes
(breast cells, melanocytes, endothe
IB p101, p84 p110g Mainly in leukocytes
(pancreas, liver, heart, skeletal musThis quirky feature of the replicating RCAS vector allowed
the identification of the relevant oncogenic change in P3K. In
an attempt to reconstruct the fusion that occurs during RCAS
replication, we experimentally joined wild-type cellular p110a
to Gag sequences and expressed the resulting hybrid product in
chicken embryo fibroblasts (Aoki et al., 2000). This chimeric
protein induced robust oncogenic transformation. These results
show that the point mutations and the N-terminal deletion
identified in viral P3K are not required for oncogenicity; an N-
terminal fusion to Gag is sufficient. Viral Gag proteins
translocate to the plasma membrane and this selective cellular
placement appears to be the most likely function leading to the
activation of the latent oncogenicity of p110a (Verderame et
al., 1996; Wills et al., 1991). This supposition was confirmed
by adding a myristylation signal to the N-terminus of the wild-
type, cellular p110a or a farnesylation signal to the C-terminus
(Aoki et al., 2000). These two constructs with an engineered
membrane address were highly oncogenic. We now use the
myristylated p110a as the standard oncogenic version of P3K.
The p110amolecule contains the following domains (Fig. 2):
an N-terminal region required for interaction with the regulatory
subunit p85, a Ras binding site, C2 domain, helical domain and a
C-terminal kinase domain (Cantley, 2002; Fruman et al., 1998;
Vanhaesebroeck and Waterfield, 1999). Analysis of the viral
P3K by introducing deletions and point mutations revealed two
other important properties of oncogenic PI3K. The N-terminal
region that binds to the regulatory subunit p85 can be deleted,
and binding to Ras can be mutationally inactivated without
abolishing oncogenicity (Aoki et al., 2000). There exists another
oncogenic avian retrovirus, ASV8905, that also carries a P3K
insert but with the p85-binding region deleted (Aoki et al.,
2000). The oncogenic potential of ASV8905 is identical to that
of ASV16. This observation reflects the fact that membrane-Upstream stimulator Knockout model
Receptor tyrosine kinases, Ras Embryonic death




Receptor tyrosine kinases, Ras Viable; immunological defect
cles)
Receptor tyrosine kinases, Ras,
G-protein-coupled receptors
Viable; immunological defect
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upstream input mediated by either p85 or Ras. In contrast,
mutations that eliminate the kinase activity of myristylated
p110a also lead to a complete inactivation of transforming
potential (Aoki et al., 2000).
Akt and TOR, essential mediators of P3K oncogenicity
The product of p110a, phosphoinositide 3,4,5 trisphosphate
(PIP3), functions as an important second messenger in the cell. It
recruits proteins that have a pleckstrin homology domain to the
cell membrane and facilitates their interactions (Corvera and
Czech, 1998). Among these downstream targets of PI3K are the
serine–threonine protein kinase Akt, also referred to as PKB,
and the phosphoinositide-dependent kinase PDK1 (Anderson et
al., 1998; Andjelkovic et al., 1997; Stephens et al., 1998; Stokoe
et al., 1997). Akt was originally identified as an oncoprotein
encoded by the genome of a murine lymphoma virus, so its
oncogenic potential was evident from the start (Bellacosa et al.,
1991; Staal, 1987). It is activated by phosphorylation mediated
by PDK1 and by a second kinase, PDK2. The identity of PDK2
has not been positively determined; current candidates are
integrin-linked kinase, Akt itself, PDK1, DNA-dependent
protein kinase or the TOR/Rictor complex (Alessi et al., 1997;
Balendran et al., 1999; Feng et al., 2004; Persad et al., 2001;
Sarbassov et al., 2005; Stephens et al., 1998; Toker and Newton,
2000). The requirements for oncogenicity of Akt are strikingly
similar to those of P3K. They include a membrane address
provided by Gag sequences or an engineered myristylation
signal and require an intact kinase domain (Aoki et al., 1998). In
the avian host, myristylated Akt induces the same type of tumors
as p110a, namely hemangiosarcomas (Aoki et al., 1998). The
oncogenic signal issued by P3K goes through Akt as an
obligatory downstream component. Dominant negative Akt
interferes specifically with P3K-induced oncogenesis, but it
does not affect transformation by unrelated oncoproteins such as
Src (Aoki et al., 1998). Akt activates the large kinase TOR (target
of rapamycin). The signal from Akt to TOR travels through the
intermediates TSC (tuberous sclerosis complex) and the small
GTPase Rheb (Garami et al., 2003; Inoki et al., 2003; Inoki et al.,
2002; Long et al., 2005; Nave et al., 1999; Saucedo et al., 2003;
Sekulic et al., 2000; Tee et al., 2003; Zhang et al., 2003). TSC is
inhibited by Akt, and Rheb is activated. TOR is an essential
component of the oncogenic signal emanating from P3K or Akt.
An inhibitor of TOR, the macrolide antibiotic rapamycin,
specifically and efficiently inhibits oncogenic transformation
induced by P3K or Akt, but it does not interfere with the
transforming activity of numerous other oncogenes (Aoki et al.,
2001). Phosphorylation of two downstream targets of TOR,
p70S6 kinase (S6K) and 4E-BP (eukaryotic initiation factor 4E
binding protein), is strictly correlated with P3K and Akt-induced
transformation (Aoki et al., 2001). Both S6K and 4E-BP play
important roles in the control of protein synthesis (reviewed in
Hay and Sonenberg, 2004). S6K is a positive regulator activated
by TOR, and 4E-BP is a negative regulator of protein synthesis
inactivated by TOR (Brunn et al., 1997; Burnett et al., 1998;
Chung et al., 1992; Gingras et al., 1998; Kuo et al., 1992; Price etal., 1992). The essential role of TOR in P3K- and Akt-induced
transformation and the correlation with S6K and 4E-BP
phosphorylation strongly implicate stimulation of protein
synthesis as an essential step in the transformation process.
YB-1: inhibition of translation and interference with
PI3K-dependent transformation
The importance of protein synthesis in the oncogenicity of
P3K andAkt is also underlined by data on the protein YB-1. YB-
1 can bind DNA and RNA and functions as a transcription factor
and as a regulator of translation (Evdokimova and Ovchinnikov,
1999; Kohno et al., 2003). It is down-regulated at the mRNA
level in cells transformed by Akt (Bader et al., 2003). Expression
of YB-1 from a retroviral vector renders chicken embryo
fibroblasts highly resistant to oncogenic transformation by
P3K or Akt, while preserving full susceptibility to the actions
of other oncogenic proteins (Bader et al., 2003). These effects of
YB-1 are similar to the ones seen with rapamycin, but the
mechanism of YB-1 action is different. YB-1 does not interfere
with TOR; the phosphorylation of the downstream targets of
TOR, 4E-BP and S6K, is unaffected (Bader et al., 2003). An
extensive deletion and mutation analysis of YB-1 has identified
the minimal part of the protein that can induce resistance to P3K-
and Akt-dependent transformation (Bader and Vogt, 2005). This
minimal interfering protein includes the centrally located cold
shock nucleic acid binding domain and much of the C-terminal
portion of YB-1. Most sequences N-terminal to the cold shock
domain are dispensable. The ability of YB-1 to inhibit protein
synthesis is tightly correlated with the induction of resistance to
oncogenic transformation (Bader and Vogt, 2005). Other
properties that correlate with resistance to transformation fall
into the category of ‘‘necessary but not sufficient’’ and include
cytoplasmic localization, homodimerization and mRNA bind-
ing. The data are in accord with the suggestion that YB-1 binds
to mRNA and reduces the efficiency of translation. While this
may not have a dramatic effect on housekeeping genes that are
constitutively translated, it could significantly affect the function
of several growth-promoting genes whose translation needs to
be stimulated by PI3K and Akt for transformation to take place.
The cancer-specific mutations in p110A induce gain of
function and oncogenic activity
The viral oncoprotein P3K was initially just an interesting
and useful experimental tool with no evident relevance for
human disease. However, over the past few years, evidence
began to accumulate for a gain of function in PI3K signaling in
diverse human tumors. These data include amplification or
overexpression of p110a and of Akt and inactivation or loss of
the negative regulator of P3K, the lipid phosphatase PTEN (Ali
et al., 1999; Bacus et al., 2002; Balsara et al., 2004; Bellacosa
et al., 1995; Byun et al., 2003; Cheng et al., 1992, 1996;
Depowski et al., 2001; Li et al., 1997; Liao et al., 2003; Ma et
al., 2000; Massion et al., 2004; Min et al., 2003; Miwa et al.,
1996; Nakatani et al., 1999; Pedrero et al., 2005; Ruggeri et al.,
1998; Shayesteh et al., 1999).
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limelight with the discovery of cancer-specific point mutations
in PIK3CA, the gene coding for p110a (Bachman et al., 2004;
Broderick et al., 2004; Campbell et al., 2004; Hartmann et al.,
2005; Lee et al., 2005; Levine et al., 2005; Li et al., 2005; Saal
et al., 2005; Samuels et al., 2004; Wang et al., 2005). These
mutations do not map randomly over the extent of the gene.
Rather, they are concentrated in distinct hot spots, suggesting
that they confer a selective growth advantage to the cell. With
these findings, the P3K oncoprotein and the effective transfor-
mation system in avian cell cultures ceased to be esoteric and
obscure sidelines of experimental cancer biology and became
highly relevant for human cancer, offering unique tools for the
investigation of p110a mutations.
We have chosen the three most prominent cancer-specific
hot-spot mutations identified in human p110a (E542K, E545K,
and H1047R) for a characterization of their oncogenic potential.
E542K and E545K are located in the helical domain of the
protein, whereas H1047R maps to the kinase domain. We
introduced these mutations into the chicken p110a gene which is
closely homologous to its human counterpart and expressed the
mutant proteins with the replication-competent avian retroviral
vector RCAS. The wild-type p110a served as a negative non-
oncogenic control; and the myristylated version of wild-type
p110a was used as positive, highly oncogenic control. All three
mutant p110a proteins induced oncogenic transformation in
cultures of chicken embryo fibroblasts (Kang et al., 2005a,
2005b). The transformed cells showed activation of the PI3K
target Akt as demonstrated by constitutive phosphorylation of
Akt, even under conditions of serum starvation. Downstream
components of the Akt signaling pathway S6K and 4E-BP were
also constitutively phosphorylated (Kang et al., 2005a, 2005b).
S6K and 4E-BP are controlled by TOR, and transformation
induced by the p110a mutants was highly sensitive to the TOR
inhibitor rapamycin, similar to oncogenic transformation in-
duced by the positive control, myristylated p110a (Kang et al.,
2005a, 2005b). These observations show that TOR signaling
mediated by S6K and 4E-BP is essential for oncogenic
transformation induced by the cancer-specific p110a mutants
and suggests an important role for the control of protein
synthesis in the transformation process, similar to the situation
that has been described for the viral oncoproteins P3K and Akt
(Aoki et al., 2001). Most of the less frequently occurring cancer-
specific mutations of p110a also posses oncogenic potential and
can transform cells in culture (Ikenoue et al., 2005; Gymnopou-
los and Vogt, unpublished data).
In enzyme assays measuring the lipid kinase activity of
PI3K, the p110a proteins carrying one of the hot-spot mutations
show a clear gain of function, with enzymatic activity levels
comparable to those of the myristylated p110a (Ikenoue et al.,
2005; Kang et al., 2005a, 2005b; Samuels et al., 2004). The
mechanisms by which mutant p110a proteins acquire a gain in
enzymatic function are not known. Three possible explanations
can be considered: mutation-induced conformational change,
altered binding to an interacting protein, and changed interac-
tion with substrate or cofactor (Kang et al., 2005a, 2005b).
There is no structure available for p110a. However, a model ofthe C-terminal portion of p110a can be derived from the
published structure of the related isoform, p110g (Walker et al.,
1999). In this model, the helical domain mutations, E542K and
E545K, map on the surface of the molecule, an unlikely
location for inducing a conformational change. Since these
mutations are distant from the kinase domain, they probably do
not affect substrate or cofactor binding. The location of these
mutations is consistent with a change in the binding to an
interacting protein, but no regulatory protein that interacts with
the helical domain has been identified. The H1047R mutation is
close to the presumed substrate pocket and could affect protein
conformation or substrate affinity. A definitive molecular and
mechanistic explanation for the increased enzymatic activity of
the p110a mutants will require more precise structural and
additional biochemical data.
We tested the three hot-spot mutations E542K, E545K, and
H1047R for their in vivo oncogenicity by inoculation of the
chorioallantoic membrane of chicken embryos. All three
mutant proteins induced neoplastic growth and were strongly
angiogenic on the chorioallantoic membrane (Bader and Vogt,
unpublished data). When injected into the wing web of young
chickens, the three mutant p110a proteins also caused the
formation of tumors. These were highly vascularized heman-
giosarcomas containing polymorphic, invasive mysenchymal
cells and large, highly abnormal blood channels with defective
endothelial linings. The H1047R mutant was the most potently
oncogenic of the three, inducing the highest incidence of tumor
formation and the most rapidly growing tumors (Bader and
Vogt, unpublished data).
In all experiments with the p110a mutants in avian cells, the
proteins were expressed with the RCAS vector. This raised the
possibility that during replication of these vector constructs,
fusions of the mutant proteins to Gag sequences could arise and
that the oncogenic activity was not due to the mutations but
rather was a result of a fusion to Gag, similar to the Gag-
dependent acquisition of oncogenic potential by wild-type
p110a as described above (Aoki et al., 2000). In order to
examine this possibility, we isolated single transformed cell foci
induced by the mutant proteins. Judging form he results with
wild-type p110a, such foci would contain the progeny of a
discrete fusion event, detectable in Western blots with p110a
and Gag antibodies as a greater than 110-kDa protein band. No
such fusions were detected when the isolated mutant-induced
foci were grown into mass culture and then examined for the
presence of chimeric Gag-p110a proteins (Kang et al., 2005a,
2005b). In contrast, all the rare foci appearing in p110a-ex-
pressing control cell cultures contained Gag fusions. These ob-
servations show that the mutant p110a proteins themselves are
oncogenic and do not require fusion to Gag to transform cells.
Oncogenic transformation induced by wild-type isoforms of
class I PI3K
Class I PI3K contains four catalytic subunit isoforms p110a,
p110h, p110g and p110y (Table 1). In contrast to the well
documented involvement of the a isoform in human cancer, the
other isoforms have been linked much less frequently to
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and glioblastomas show increased expression of the p110h and
p110y isoforms (Benistant et al., 2000; Mizoguchi et al., 2004).
Knockdown experiments suggest a functional role of the h
isoform in cell proliferation and invasive cell growth (Czau-
derna et al., 2003). The y isoform mediates Akt activation and
thereby contributes to cell proliferation in acute myeloid
leukemia (Sujobert et al., 2005). The g isoform has so far
not been implicated in cell growth and tumorigenesis. The h, g
and y isoforms share similar structural organization with the a
isoform (Okkenhaug and Vanhaesebroeck, 2003; Vanhaeseb-
roeck et al., 1997; Wymann et al., 2003). The a and h isoforms
are ubiquitously expressed, whereas y and g isoforms occur
predominantly in leukocytes. Response to upstream signals is
tied to receptor tyrosine kinases in case of the a and y isoforms;
the g isoform is stimulated by G-protein-coupled receptors and
the h isoform can accept input from both receptor tyrosine
kinases and from G-protein-coupled receptors (Kurosu et al.,
1997; Maier et al., 1999; Murga et al., 2000). Genetic
inactivation of p110a or p110h leads to early embryonal
death, whereas knockout models of the y and g isoforms are
viable and fertile but show deficiencies in their immune
responses (Foukas and Okkenhaug, 2003). Because of the
distinct properties of the h, g and y isoforms and their less
prominent ties to cancer, we tested the catalytic subunits of h, g
and y for their oncogenic potential, fully expecting that these
wild-type proteins would not initiate oncogenic changes in
chicken embryo fibroblasts. The expectation was wrong; the h,
g and y catalytic subunits expressed in chicken embryo
fibroblasts transform these cells (Kang and Vogt, unpublished
data). The h isoform shows the weakest and y the strongest
transforming activity. Addition of a myristylation signal to
these wild-type proteins enhances transforming activity signif-
icantly in the case of the h isoform and marginally in the
already potent y and g isoforms. Tests for possible fusions to
Gag sequences that could facilitate the oncogenicity of these
proteins turned out negative. The latent oncogenicity of the h,
g and y isoforms revealed by overexpression may explain why
mutations in these isoforms of p110 have not been found in
human cancer. Since mere overexpression of the wild-type
proteins can drive cell replication, an oncogenic effect may be
achieved by enhanced expression; gain of function mutations
may not be necessary. The transforming activity of the class I
isoforms appears to make use of different downstream
signaling pathways: only the a (as determined by the
H1047R mutant) and y isoforms activate Akt, under conditions
of serum starvation, the h and g isoforms do not enhance Akt
activity. The h, and g isoforms are activated by G-protein-
coupled receptors (Kurosu et al., 1997; Maier et al., 1999). In
contrast, the a and y isoforms are not stimulated by G-protein-
coupled receptors but receive input from receptor tyrosine
kinases (Maier et al., 1999; Wymann et al., 2003). In agreement
with these different upstream and downstream signaling
pathways, inactivating mutations of the Ras-binding domain
have no effect on the oncogenicity of the a and y isoforms but
significantly reduce the transforming potential of the h and g
isoforms (Kang and Vogt, unpublished data).Mutated p110A as a drug target
The mutated versions of the p110a proteins are ideal
targets for small molecule inhibitors and offer a unique
opportunity to develop new, highly selective anti-cancer
drugs. The mutations in these proteins are cancer-specific,
and they cause a gain of function. The mutated proteins are
enzymes. These favorable attributes could be used in the
design of mutant-specific small molecule inhibitors. Such
inhibitors would not interfere with the normal function of
wild-type p110a and therefore should have no or minimal
toxicity. In particular, the mutant-specific inhibitors would
not affect insulin signaling which is dependent on PI3K.
Identifying such inhibitors will be difficult but not impossi-
ble. The new technique of click chemistry may show a way
(Kolb et al., 2001). Click chemistry generates bivalent
enzyme inhibitors of great potency and specificity. The
inhibitors are assembled by the target protein from a library
of small molecule ligands that bind to the target with
moderate affinity. The small molecules are decorated with
complementary reactive groups that establish a covalent link
between two ligands that attach to the target in close
proximity. The H1047R mutant of p110a appears most
suitable for this approach. The two interacting ligands could
be directed to the ATP pocket and the mutated region, close
enough to allow a covalent link to form between these
ligands. The assembled biligand is detectable and identifiable
by mass spectrometry. Application of click chemistry to
model enzyme systems has generated extremely encouraging
results (Krasinski et al., 2005; Manetsch et al., 2004;
Mocharla et al., 2004). The mutant structure could be the
basis of specificity and the attachment of a second ligand by
click chemistry could generate the requisite potency of
binding. In the past few years, targeted cancer therapy that
aims at a tumor-specific protein has emerged with several
remarkable successes. These include Imatinib (Gleevec) a
small molecule drug that inhibits BCR-ABL, KIT and PDGF
(Druker et al., 2001; O’Brien et al., 2003), Trastuzumab
(Herceptin), a monoclonal antibody directed against the ERB-
B2/HER-2 receptor tyrosine kinase, and Gefitinib (Iressa) and
Erlotinib (Tarceva) which inhibit the EGF receptor (Lynch et
al., 2004; Paez et al., 2004; Pao et al., 2004; Shepard et al.,
1991; Yu and Hung, 2000). These also provide examples of
differential drug effects on mutant target proteins. The
successes of targeted cancer therapy so far were achieved
with conventional chemical and biological approaches. Novel
technologies, including click chemistry, can be expected to
expand this promising field substantially.
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